Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre- Approval Inspection (PAI) conducted between
Granules India Limited (BSE: 532482, NSE: GRANULES), a vertically integrated pharmaceutical company committed to sustainable and responsible healthcare, has been awarded a Gold rating by EcoVadis in its inaugural corporate-level assessment. This places the company in the 97th percentile, among the top 5% of all
